Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab Combinations in R/R FL and DLBCL
NCT02220842Phase 1Completed
- Sponsor
- Roche
- Start
- Dec 2014
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label trial of atezolizumab in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) (5 cohorts), sponsored by Roche. Primary endpoints: Percentage of Participants With Dose Limiting Toxicities at 21 days and Recommended Phase 2 Dose of Atezolizumab at 21 days. Started Dec 2014; status: completed.
02
Drugs
atezolizumab
03
Conditions
follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02220842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02220842.